Skip to content

    India Pesticides Limited

    IPL
    Chemicals·28 May 2025
    Management Summary

    India Pesticides delivered a strong Q4 and FY25, with significant revenue and EBITDA growth driven by strategic initiatives, capacity expansion, and new product registrations. While facing temporary pricing pressures and increased debt from short-term borrowings, the company is optimistic about future growth, targeting INR 1,000 crore revenue and 18-20% EBITDA margin for FY26, supported by internal accruals and a debt-free commitment.

    Highlights

    5
    • FY25 Revenue of INR 844 crore, up 21.3% YoY, demonstrating robust growth amidst a dynamic global environment.

    • FY25 EBITDA increased 32% to INR 134 crore, with EBITDA margin at 16%, driven by strategic clarity and effective execution.

    • Q4 FY25 Revenue surged 62% YoY to INR 211 crore, and EBITDA jumped 373% to INR 35 crore, indicating strong quarterly recovery.

    • PAT margin expanded 950 bps to 10% in Q4 FY25, reflecting improved operating leverage and price stability.

    • Formulations business grew over 20% compounded, and Pretilachlor is expected to grow 20% compounded over the next 2-3 years, highlighting strong product-specific momentum.

    Concerns

    3
    • Temporary pricing pressure was observed in the agrochemical industry, though prices are now stabilizing.

    • Debt increased from INR 18 crore in FY24 to INR 52 crore in FY25 due to short-term borrowings, though management expects normalization.

    • Operating cash flow was significantly low at INR 2 crore in FY25, attributed to increased debtor levels and strategic inventory buildup.

    What Changed1

    vs Q1 FY26

    Guidance items15 → 7 (-8)

    Key financials

    Single quarter

    07 metrics
    1. 01Revenue₹844 Cr+21.3%YoY
    2. 02EBITDA₹134 Cr+32%YoY
    3. 03EBITDA Margin16%
    4. 04Net Profit₹82 Cr+37%YoY
    5. 05PAT Margin9.7%

    Segment breakdown

    • Technicals (FY25)₹549 Cr66.2%
    • Formulations (FY25)₹280 Cr33.8%
    Donut· Share of Revenue

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹116 crores

    internal accruals

    Debt

    Gross ₹52 crores

    Liquidity

    Liquidity disclosed

    Committed to maintaining a debt-free position, funding all expansions and investment from internal accruals.

    Guidance & targets

    7
    CategoryTargetPriority
    Revenue
    Revenue Target
    INR 1,000 crores
    High
    Revenue
    Revenue Growth
    15% to 20%
    Medium
    Margin
    EBITDA Margin
    18% and 20%
    High
    Product Growth
    Pretilachlor Growth
    20% compounded
    High
    Product Growth
    Formulations Business Growth
    >20% compounded
    High
    Working Capital
    Normalized Working Capital Days
    around 220 days
    High
    Capacity Utilization
    Sandila Unit Peak Revenue
    around INR 1,100 crore
    Medium

    What to watch in Q1 FY26

    5

    Shalvis Specialities Limited commercial operations

    Next quarter
    CurrentProgressing well, under construction
    TargetCommercial operations started

    Why it matters

    Shalvis is a key capex project, and its commercialization will contribute to future revenue and profitability.

    It will start contributing from next quarter only. We will be building the Shalvis in small blocks and it starts with contributing step by step.

    Risks & concerns

    4
    RiskSeverity

    Temporary pricing pressure in agrochemical industry

    Temporary pricing pressure was observed, though recent quarters show signs of stabilization.Management acknowledged

    medium

    Increased debt due to short-term borrowings

    Debt increased from INR 18 crore in FY24 to INR 52 crore in FY25, but management expects it to be normalized soon.Management acknowledged

    low

    Low operating cash flow due to increased debtor days and strategic inventory buildup

    Operating cash flow was INR 2 crore in FY25 due to delayed customer remittances and a strategic decision to hold higher inventory for seasonal demand.Management acknowledged

    medium

    Fluctuating export demand due to geographical and weather conditions

    Export demand is difficult to predict as geographical and weather conditions are constantly changing, leading to demand fluctuations across regions.Management acknowledged

    medium

    Q&A highlights

    8

    “With the early monsoon, we feel that the pick-up of the agrochemicals would be little earlier. So there has to be a good demand for agrochemicals, especially during sowing, the herbicide requirement will certainly increase. ... raw material prices are getting stabilized and they are more or less stable now.”

    Addresses immediate demand outlook and cost stability, crucial for margin and operational planning.

    asked by Shreya Jain

    2 min read6 chapters

    Detailed Narrative

    01

    Robust FY25 Performance and Strategic Growth Drivers

    India Pesticides reported a strong FY25 with revenue growing 21.3% YoY to INR 844 crore and EBITDA increasing 32% to INR 134 crore, achieving a 16% margin. This performance was driven by strategic clarity, effective execution, and a differentiated product portfolio. Management highlighted increased capacity utilization, new product introductions, and backward integration as key drivers for future growth, aiming for INR 1,000 crore revenue and 18-20% EBITDA margin in FY26.

    02

    Capacity Expansion and Debt-Free Commitment

    The company has planned a capex of INR 116 crore for FY26, with over INR 200 crore projected over two years, focusing on existing facilities and Shalvis Specialities Limited. This includes INR 52 crore for the existing facility and INR 64 crore for Shalvis, along with investments in a boiler and new production complexes at Sandila. Despite these investments, IPL remains committed to maintaining a debt-free position, funding all expansions through internal accruals.

    03

    Formulations and Pretilachlor as Key Growth Engines

    The formulations business demonstrated strong growth, exceeding 20% compounded, with bulk formulation exports increasing significantly from INR 10-12 crore to INR 50 crore. Pretilachlor, a major rice herbicide, is expected to see significant jumps with 20% compounded growth over the next 2-3 years, driven by increased capacity. The company anticipates over INR 100 crore in sales from Pretilachlor in FY25, with its 8,500-ton capacity potentially generating over INR 300 crore.

    04

    Market Diversification and Regulated Market Penetration

    IPL is broadening its market reach, establishing a stronger presence in over 25 regulated markets. In FY25, the company secured 4 technical and 19 formulation registrations in India, along with 4 registrations in EU/UK and 2 in USA, plus 2 formulation registrations in Australia. Commercial supplies for one US-registered product have already begun, with orders expected for another soon, reinforcing IPL's position as a reliable global partner.

    05

    Working Capital and Cash Flow Management

    Operating cash flow for FY25 was significantly low at INR 2 crore, primarily due to an increase in debtor levels as some large buyers remitted payments in April instead of March. Additionally, IPL strategically increased inventory to cater to MNC customers with shorter order cycles and avoid losing seasonal demand. Management expects working capital days to normalize from ~250 days to ~220 days in the coming quarters.

    06

    Raw Material Stability and Margin Improvement Outlook

    After a period of drastic price reductions in the previous year, raw material prices are now stabilizing, contributing to margin expansion. Management attributes the projected improvement in EBITDA margins from 16% to 18-20% in FY26 to operating leverage, the introduction of new products, and backward integration initiatives. They also noted that domestic and export margins are largely on par, with minor differences related to imported raw material duties.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.